Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464448 · ClinicalTrials.gov registry record
Mechanistic Studies of Teriflunomide in RRMS
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 30
- Enrollment target
NCT03464448: Completed study, sponsored by University of Michigan.
NCT03464448 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03464448 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study is to address the mechanism of action of teriflunomide in a phase IV open label trial with Teriflunomide in multiple sclerosis. Researchers will recruit 20 relapsing remitting multiple sclerosis patients (Group 1) start on treatment with teriflunomide (Aubagio). Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. Meanwhile, 10 healthy controls will be recruited, to establish a healthy baseline for B and T cells, which are affected by both MS and its treatment (Group 2). This Study will collect baseline pre-treatment blood samples periodically for up to 2 years. Blood biomarker changes will be correlated with clinical response to teriflunomide treatment intervention.
Primary Outcome
Compare aubagio treatment to baseline and to healthy controls
Interventions
- DRUG Teriflunomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2021-10-13 |
What the finished NCT03464448 record still lists
NCT03464448 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Teriflunomide is the first listed.
NCT03464448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03464448 about?
NCT03464448 is a clinical study titled "Mechanistic Studies of Teriflunomide in RRMS". This study is to address the mechanism of action of teriflunomide in a phase IV open label trial with Teriflunomide in multiple sclerosis. Researchers will recruit 20 relapsing remitting multiple sclerosis patients (Group 1) start on treatment with teriflunomide (Aubagio). Patients will be enrolled ...
What is the current status of trial NCT03464448?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-04-17. Estimated completion is 2021-10-13.
What interventions are being tested in trial NCT03464448?
The interventions under investigation include: Teriflunomide (DRUG).
Who is sponsoring clinical trial NCT03464448?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI